Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763702 | 1.00 | CYP3A4 (0.38) | CYP3A4TDP1ESR1ESR2CA1 | |
| SCHEMBL735405 | 1.00 | CYP3A4 (0.38) | CYP3A4TDP1ESR1ESR2CA1 | |
| SCHEMBL7625046 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ESR1ESR2CA1 | |
| SCHEMBL7618395 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ESR1ESR2CA1 | |
| Hydrochloric Acid SCHEMBL2241908 | 0.97 | CYP3A4 (0.35) | CYP3A4TDP1ESR1ESR2CA1 | |
| Hydrochloric Acid SCHEMBL6760978 | 0.97 | CYP3A4 (0.35) | CYP3A4TDP1ESR1ESR2CA1 | |
| Hydrochloric Acid SCHEMBL6764244 | 0.97 | CYP3A4 (0.35) | CYP3A4TDP1ESR1ESR2CA1 | |
| SCHEMBL6763721 | 0.94 | CA2 (0.35) | CA1CA2 | |
| SCHEMBL7618005 | 0.92 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL3003099 | 0.90 | CA1 (0.34) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019016115-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED ARYL KETONES | BASF Agro B.V. (NL) | 2019-01-24 | — | — | WO | claimed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | claimed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | claimed |
| CN-118324848-A | Process for preparing cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2024-07-12 | — | — | CN | disclosed |
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4361128-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-112996792-B | Process for preparing cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3880681-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4286387-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-110225904-B | Process for preparing cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1899322-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | CYP3A4 40/4885TDP1 2164/4885ESR1 1837/4885 |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | CYP3A4 3069/4885TDP1 1717/4885ESR1 1558/4885 |
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | CYP3A4 40/4885TDP1 2164/4885ESR1 1837/4885 |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | PIGO, MANBA, OAT | CYP3A4 1349/4885TDP1 869/4885ESR1 3649/4885 |
| US-20090088441-A1 | Quinoline Compounds | GABRB1, HRH2, GABRA5 | CYP3A4 969/4885TDP1 2834/4885ESR1 2037/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CYP3A4 1550/4885TDP1 2080/4885ESR1 927/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | CYP3A4 4269/4885TDP1 1637/4885ESR1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.